Diabetes & Metabolism Journal · 2018 · 32 citations · 8 references
MedicineEndocrinologyPharmacologyDiabetologyMolecular PharmacologyRenal PathophysiologyDiabetes ManagementDiabetes MellitusDiabetes PharmacotherapyDiabetic NephropathyDiabetic NeuropathySodium-glucose Cotransporter 2 InhibitorsAfferent Nerve FibersAntidiabetic ActivityAntidiabetic Drug TherapyIntraepidermal Nerve Fiber DensityMesangial ExpansionPeripheral Neuropathy Skin ChangesSodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
The effect of sodium-glucose cotransporter 2 inhibitors on peripheral nerves and kidneys in diabetes mellitus (DM) remains unexplored. Therefore, this study aimed to explore the effect of empagliflozin in diabetic rats. DM in rats was induced by streptozotocin injection, and diabetic rats were treated with empagliflozin 3 or 10 mg/kg. Following 24-week treatment, response thresholds to four different stimuli were tested and found to be lower in diabetic rats than in normal rats. Empagliflozin significantly prevented hypersensitivity (P<0.05) and the loss of skin intraepidermal nerve fibers, and mesangial matrix expansion in diabetic rats. Results of this study demonstrate the potential therapeutic effects of empagliflozin for the treatment of diabetic peripheral neuropathy and nephropathy.
8
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner, Silvio E. Inzucchi, John M. Lachin et al. · New England Journal of Medicine · 2016 · 3.6K citations · Full text